Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 13 of 13 publications.

Yousif Z, Schultz BG, Candela N, Harold S, Bell J, Turpin R, Hartley L. Systematic literature review to evaluate randomized clinical trials of advanced therapies for moderate to severe crohn's disease. Poster presented at the ISPOR 2023 Conference; May 6, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S15. doi: 10.1016/j.jval.2023.03.085

Saidha S, Bell J, Harold S, Belisario JM, Hawe E, Shao Q, Wyse K, Maiese EM. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurol Sci. 2023 May;44(5):1515-32. doi: 10.1007/s10072-022-06582-y

Yucel E, Hartley L, Bell J, Wolowacz S, Kamgar F, Hawe E. A systematic literature review of utility estimates for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S395. doi: 10.1016/j.jval.2022.09.1964

Saidha S, Bell J, Harold SE, Marcano Belisario JS, Hawe E, Shao Q, Wyse K, Maiese EM. A systematic literature review of immunoglobulin levels among B-cell–depleting therapies and risk of infections in relapsing multiple sclerosis. Poster presented at the 2022 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting; June 1, 2022. National Harbor, MD.

Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Subcutaneous immunoglobulin use in immunoglobulin-naïve patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022 Apr;14(5):373-87. doi: 10.2217/imt-2021-0265

DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-47. doi: 10.2217/fon-2021-0742

Michaud K, Pope J, van de Laar M, Curtis JR, Kannowski C, Mitchell S, Bell J, Workman J, Paik J, Cardoso A, Taylor PC. A systematic literature review of residual symptoms and unmet need in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021 Nov;73(11):1606-16. doi: 10.1002/acr.24369

Ahdesmaki O, Ainsworth C, Bell J, Hawe E. Ongoing SLRs when considering HTA submissions: rewards and avoidable pitfalls. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.

Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9

Robbins PB, Krieger T, Pearson I, Bell J, Doherty J. Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment. Poster presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium; March 1, 2019. San Francisco, CA.

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. In reply: Network meta-analyses are not about a single treatment but about sets of regimens. Clin Ther. 2019 Jan;41(1):188-90. doi: 10.1016/j.clinthera.2018.11.011

Doyle S, Moss E, Hartley L, Knight C, Bell J, Ahdesmaki O, Kelly M. An economic systematic literature review of eosinophilic granulomatosis with polyangiitis. Poster presented at the 2018 ACR/ARHP Annual Meeting; October 22, 2018. Chicago, IL. [abstract] Arthritis Rheumatol. 2018 Sep; 70(S9):1953. doi: 10.1002/art.40700

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018 Mar;40(3):480-94. doi: 10.1016/j.clinthera.2018.01.014